Based on the significant unmet need in Alzheimers disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutides potential, despite a low likelihood of success, Martin Holst Lange, chief scientific officer at Novo Nordisk said in a press release
Author Contributions The authors directed the content and reviewed and critically revised all drafts
Novo Nordisk may attempt to mitigate the impact from off-patent competition by protecting their share of Wegovy by enhancing weight-management services, or migrating patients from semaglutide to newer, patent-protected AOMs, including offering an oral version of semaglutide, effectively offering therapies with greater patient benefits
A limitation to the study is the use of mortality risk prediction equations from the UKPDS-OM2
For example, blood sugar levels may rise again after stopping